Tag Archive | "Kyowa Hakko Kirin"

Top 50 Pharma (top pharmaceutical companies)

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

The term ‘top pharma’ can relate to the top pharmaceutical companies or the top 10 or 50… Read the full story

Activiomics extends pharma alliances with Kyowa Hakko Kirin

Tags: , , ,

Activiomics has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin by entering into a new pharma alliances research programme Read the full story

Kyowa Hakko Kirin pharma deals Ultragenyx for KRN23 license

Tags: , , ,

Ultragenyx Pharmaceutical has entered into pharma deals with Kyowa Hakko Kirin, to develop and commercialize KRN23. Read the full story

Kyowa Hakko Kirin: Company Profile

Tags: ,

Kyowa Hakko Kirin, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Kyowa Hakko Kirin in biotech partnering with Ezose Sciences

Tags: , , ,

Ezose Sciences has entered into a biotech partnering deal with Kyowa Hakko Kirin, a big pharma company, to collaborate on glycomics studies using Ezose’s proprietary GlycanMap technology platform Read the full story

Kyowa Hakko pharma alliances with NovAliX

Tags: , , ,

NovAliX has entered into a pharma alliances agreement, for development of fragment-based drug discovery, with bigpharma Kyowa Hakko Kirin Read the full story

Big pharma Kyowa Hakko Kirin pharma partners with Anchor Therapeutics for its pepducin technology

Tags: , , , ,

Anchor Therapeutics has entered into a collaborative pharma partners agreement with Kyowa Hakko Kirin to utilize Anchor’s proprietary pepducin technology to advance KHK’s internal G protein-coupled receptor drug discovery portfolio.

Read the full story

Partnering Agreements with Kyowa Hakko Kirin

Tags: , , , , , , ,

This report provides all the information you require to better understand Kyowa Hakko Kirin and its partnering interests and activities over the past seven years.  Read the full story

H. Lundbeck A/S Enters Into License Agreement With Kyowa Hakko Kirin For A2a Antagonists For Parkinson’s and Other Indications

Tags: , ,

Agreement with Kyowa Hakko Kirin providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Read the full story

Biovail to pay Kyowa Hakko Kirin up to $65 million for US and Canadian rights to Parkinson’s drug

Tags: ,

BLS has paid an upfront fee of $10 million, and could pay up to $20 million in potential development milestones through U.S. Food and Drug Administration (FDA) approval and up to an additional $35 million if certain sales-based milestones are met. Read the full story

RSS Feed Linked In Twitter

Latest Tweets